Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 14 2025
0mins
Source: Globenewswire
Collaboration Announcement: Acumen Pharmaceuticals and JCR Pharmaceuticals have formed a partnership to develop an Enhanced Brain Delivery therapy targeting amyloid beta oligomers for Alzheimer's disease, with preclinical data expected in early 2026.
Product Development Focus: The collaboration aims to leverage Acumen's expertise in AβO-selective antibodies and JCR's blood-brain barrier-penetrating technology to create next-generation treatment options, while Acumen's lead program, sabirnetug, is currently undergoing Phase 2 clinical trials.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
